Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 5/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PRLHR | P49683 | 9/20 | 0.34 |
| ▸ | CLPP | Q16740 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30283970 | 1.00 | MTHFD2 (0.37) | MTHFD2ROCK2CYP3A4MAPTPRLHR | |
| SCHEMBL25363775 | 0.93 | ROCK2 (0.42) | MTHFD2ROCK2CYP3A4MAPTPRLHR | |
| SCHEMBL23973811 | 0.93 | ROCK2 (0.42) | MTHFD2ROCK2CYP3A4MAPTPRLHR | |
| SCHEMBL23972726 | 0.93 | MTHFD2 (0.41) | MTHFD2ROCK2CYP3A4MAPTCLPP | |
| SCHEMBL30283932 | 0.93 | MTHFD2 (0.41) | MTHFD2ROCK2CYP3A4MAPTCLPP | |
| SCHEMBL30283762 | 0.92 | THRB (0.37) | MTHFD2MAPTCLPP | |
| SCHEMBL23973030 | 0.92 | THRB (0.37) | MTHFD2MAPTCLPP | |
| SCHEMBL23973803 | 0.92 | ROCK2 (0.40) | MTHFD2ROCK2CYP3A4MAPTCLPP | |
| SCHEMBL23972479 | 0.88 | MTHFD2 (0.42) | MTHFD2CLPP | |
| SCHEMBL30284344 | 0.88 | MTHFD2 (0.42) | MTHFD2CLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| CN-115427409-A | Pyrimidin-4 (3H) -one derivatives as TRPV4 antagonists | 拉夸里亚创药株式会社 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021221169-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | MTHFD2 2762/4885ROCK2 3909/4885CYP3A4 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.